Spots Global Cancer Trial Database for amg 706
Every month we try and update this database with for amg 706 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open Label Treatment Extension Study of AMG 706 | NCT00360867 | Solid Tumors | AMG 706 | 18 Years - | Amgen | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer | NCT00101907 | Lung Cancer Pancreatic Canc... Esophageal Canc... | AMG 706 Panitumumab Gemcitabine Cisplatin | 18 Years - | Amgen | |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | NCT00322400 | Locally Recurre... | Docetaxel Paclitaxel AMG 706 | 18 Years - | Amgen | |
| Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | NCT00448786 | Solid Tumors | AMG 706 AMG 706 AMG 706 | 18 Years - | Amgen | |
| Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors | NCT00254267 | Advanced Gastro... | AMG 706 | 20 Years - | Amgen | |
| Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors | NCT01386866 | Advanced Solid ... | AMG 706 | 18 Years - | Amgen | |
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer | NCT00121628 | Thyroid Cancer | AMG 706 | 18 Years - | Amgen | |
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | NCT00093873 | Tumors | Anti-angiogenes... AMG 706 | 18 Years - | Amgen | |
| A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | NCT00369070 | Advanced Non-sq... | Bevacizumab AMG 706 Paclitaxel Carboplatin | 18 Years - | Amgen | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) | NCT00089960 | Gastrointestina... | AMG 706 | 18 Years - | Amgen | |
| Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | NCT00101894 | Rectal Cancer Colon Cancer | FOLFOX-4 AMG 706 Panitumumab (Pa... FOLFIRI | 18 Years - | Amgen | |
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | NCT00093873 | Tumors | Anti-angiogenes... AMG 706 | 18 Years - | Amgen | |
| Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | NCT00448786 | Solid Tumors | AMG 706 AMG 706 AMG 706 | 18 Years - | Amgen | |
| Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors | NCT00254267 | Advanced Gastro... | AMG 706 | 20 Years - | Amgen | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | NCT00101894 | Rectal Cancer Colon Cancer | FOLFOX-4 AMG 706 Panitumumab (Pa... FOLFIRI | 18 Years - | Amgen | |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | NCT00356681 | Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre... | AMG 706 placebo Bevacizumab AMG 706 Paclitaxel | 18 Years - | Amgen | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | NCT00369070 | Advanced Non-sq... | Bevacizumab AMG 706 Paclitaxel Carboplatin | 18 Years - | Amgen | |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | NCT00356681 | Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre... | AMG 706 placebo Bevacizumab AMG 706 Paclitaxel | 18 Years - | Amgen | |
| An Open Label Treatment Extension Study of AMG 706 | NCT00360867 | Solid Tumors | AMG 706 | 18 Years - | Amgen | |
| A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | NCT00369070 | Advanced Non-sq... | Bevacizumab AMG 706 Paclitaxel Carboplatin | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
